About Biogen
What Biogen is building
Funding rounds
Company type
Biogen news and updates
Al Sandrock leaves Biogen, Inc. as CEO
“I think we're entering into a very exciting era for neurotherapeutics,” said Al Sandrock, former Biogen executive and current CEO of gene therapy and neuroscience-focused Voyager Therapeutics.
Dec 20, 2022 | biospace.comBiogen, Inc. partners with Genentech
Biogen’s collaboration with Genentech could pay off again in the form of US royalties for the potential blood cancer drug glofitamab, a CD20xCD3 bispecific.
Dec 18, 2022 | sfbn.orgBiogen, Inc. launches hands-on biotech laboratory program for middle and high schoolers
By way of quick examples, 3M is investing in programs that support academic achievements for underrepresented students, and Biogen is launching a hands-on biotech laboratory program for middle and high schoolers.
Dec 13, 2022 | fortune.comBiogen, Inc. is developing BIIB800 on Apr 1st 21'.
Biogen announced in April 2021 that it entered into a commercialization and license agreement with Bio-Thera Solutions, Ltd. to develop, manufacture and commercialize BIIB800.
Dec 8, 2022 | pipelinereview.comRobert Francis leaves Biogen, Inc. as CEO
Robert Francis, former CEO of Sandoz and an executive at Novartis AG NVS, -0.31% and former executive at Biogen Inc.
Nov 21, 2022 | marketwatch.comFranchimont leaves Biogen, Inc. as Senior Vice President, Head of Multiple Sclerosis and Immunology Development Unit
Dr. Franchimont joins Nimbus from Biogen, where she served as Senior Vice President, Head of Multiple Sclerosis and Immunology Development Unit.
Oct 26, 2022 | biospace.comBiogen, Inc. partners with National Minority Quality Forum
Additionally, Biogen co-developed a paper with the NMQF titled “A Roadmap for Real-World Evidence Generation in Alzheimer’s Disease.”
Oct 23, 2022 | atlanta-georgia-dui.comGoodRx Inc. partners with Biogen, Inc.
As part of the launch, GoodRx has partnered with Cambridge, Massachusetts-based Biogen, a pharmaceutical company that has developed a specialty drug for multiple sclerosis, Vumerity.
Oct 13, 2022 | modernhealthcare.comPharmacy Today partners with Biogen, Inc.
The evidence is clear that nusinersen can benefit people with spinal muscular atrophy, so Pharmacy Today is pleased to have reached an agreement with Biogen.
Sep 27, 2022 | pharmacytoday.co.nzBiogen, Inc. sells assets to Boston Properties Inc. in the amount of $603M
Biogen Inc. has sold a six-floor lab building in Kendall Square to Boston Properties Inc. for $603 million and ended its lease early on a nearby office building, as part of its continued drive to shrink its real estate footprint.
Sep 20, 2022 | bizjournals.comBiogen, Inc. filed suit against Polpharma Biologics Group on Sep 9th 22'.
On September 9, 2022, Biogen filed a complaint in the District of Delaware against Sandoz and Polpharma Biologics.
Sep 13, 2022 | jdsupra.comBiogen, Inc. has issues with alleged illegal kickback scheme
Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB) relating to possible false and misleading statements to investors about its Alzheimer’s drug Aduhelm and an alleged illegal kickback scheme.
Sep 9, 2022 | classactionlawyers.comBiogen, Inc. launches mid-stage monoclonal antibody, litifilimab
Biogen announced that its mid-stage monoclonal antibody, litifilimab, is showing promise in reducing joint pain related to systemic lupus erythematosus (SLE) lupus.
Sep 8, 2022 | biospace.comBiogen, Inc. is developing Xcimzane on Feb 1st 22'.
In February 2022, Biogen Inc. and Xbrane Biopharma AB announced that they have entered into a commercialization and license agreement to develop, manufacture, and commercialize Xcimzane ™, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA® (certolizumab pegol).
Jul 26, 2022 | yahoo.comBiogen, Inc. launches BYOOVIZ
Biogen Inc., and Samsung Bioepis Co., Ltd. today announced that BYOOVIZ™ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab)i has been launched in the United States.
Jun 2, 2022 | clival.comBiogen, Inc. expands facilities to Switzerland
Biogen is planning to produce lecanemab drug substance in its manufacturing facility in Solothurn, Switzerland, to provide commercial supply worldwide.
Mar 14, 2022 | ns-healthcare.comBiogen Inc. invests into assets : stake in the joint venture in the amount of $2.3B
Biogen will receive up to $2.3 billion for its stake in the joint venture from Samsung Biologics.
Jan 1, 2022 | imapac.comBlock & Leviton LLP files suit against Biogen, Inc.
Block & Leviton LLP ( www.blockleviton.com ), a national securities litigation firm, announces that it has filed a class action lawsuit on behalf of shareholders against Biogen, Inc. (NASDAQ: BIIB) and certain of its executives for securities fraud.
Jan 1, 2022 | globenewswire.comBiogen, Inc. decreases headcount by 100
Biogen has already laid off more than 100 employees, including two-thirds of the Alzheimer’s commercial team and all leaders within the Alzheimer’s field sales force, Endpoints News reports, citing a senior company exec.
Jan 1, 2022 | fiercepharma.comBiogen, Inc. decreases headcount by 1000
People close to Biogen have said the company will cut about 1,000 jobs — more than 10% of its workforce — through layoffs, voluntary resignations, and the elimination of open positions.
Jan 1, 2022 | statnews.comBiogen, Inc. is developing biosimilar of certolizumab pegol (Cimzia on Feb 7th 22'.
On 7 February 2022, US-based Biogen and Sweden-based Xbrane announced an agreement to develop, manufacture and commercialize a proposed biosimilar of certolizumab pegol (Cimzia, UCB).
Jan 1, 2022 | gabionline.netBiogen, Inc. launched data and updates from SPINRAZA on Mar 14th 22'.
Biogen Inc. (Nasdaq: BIIB) today announced new data and updates from its SPINRAZA ® (nusinersen) and spinal muscular atrophy (SMA) research program aimed at improving clinical outcomes for people impacted by the disease, including the ASCEND, RESPOND and NURTURE studies.
Jan 1, 2022 | infomeddnews.comBiogen, Inc. hires Simon as Vice President and Head of the Pain Therapeutic Area
Following this acquisition, Simon joined Biogen, where he assumed the role of Vice President and Head of the Pain Therapeutic Area.
Jan 1, 2022 | curasen.comBiogen, Inc. launches data showing that aducanumab-avwa injection 100 mg/mL
Biogen has announced new data showing that aducanumab-avwa (Aduhelm) injection 100 mg/mL for intravenous use continued to significantly reduce 2 key Alzheimer disease (AD) pathologies in a 128-week extension phase of a phase 3 trial.
Jan 1, 2022 | pharmacytimes.comEvrysdi identified as competitor of Biogen, Inc.
[ 1 ] Evrysdi competes with Biogen’s Spinraza.
Jan 1, 2022 | forbes.comBiogen, Inc. launches data and updates from spinal muscular atrophy research program using therapeutic nusinersen
Biogen announced new data and updates from its spinal muscular atrophy (SMA) research program using its therapeutic nusinersen (Spinraza).
Jan 1, 2022 | biospace.comBiogen, Inc. launches virtual study on cognitive decline
In 2021, Apple and Biogen launched a virtual study on cognitive decline that is currently being conducted on Apple Watch and iPhones.
Jan 1, 2022 | mobihealthnews.comBiogen, Inc. had issues with commercial failure of Aduhelm on Mar 1st 22'.
Earlier in March, it was reported that Biogen laid off more than 100 workers — the vast majority in its Alzheimer's division — as a result of commercial failure of Aduhelm.
Jan 1, 2022 | seekingalpha.comBiogen, Inc. launches West
When Biogen introduced plans for the first natural history study for KCNT1-related epilepsy, West was thrilled but had some concerns.
Jan 1, 2022 | lunadna.comBiogen, Inc. launches data from industry-leading portfolio of multiple sclerosis therapies
Biogen Inc. (Nasdaq: BIIB) today announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies being presented at the American Academy of Neurology (AAN) 2022 Annual Meeting.
Jan 1, 2022 | yahoo.comBiogen, Inc. launched BLA submission for lecanemab on Sep 1st 21'.
Last September, Eisai (ESALY) and Biogen (BIIB) announced the initiation of BLA submission for lecanemab under the accelerated approval pathway.
Jan 1, 2022 | seekingalpha.comBiogen, Inc. is developing CRISPR-based therapies on Jan 1st 20'.
In 2020, Scribe announced their research collaboration with Biogen to develop and commercialize CRISPR-based therapies that address an underlying genetic cause of Amyotrophic Lateral Sclerosis (ALS).
Jan 1, 2022 | valdostadailytimes.comBiogen, Inc. is developing MR-004
Biogen Inc. ( BIIB) and MedRhythms have entered into a license agreement to develop and commercialize MR-004, an investigational prescription digital therapeutic for the potential treatment of gait deficits in multiple sclerosis (MS).
Jan 1, 2022 | gurufocus.comBiogen, Inc. has issues with violations of the False Claims Act and Anti-Kickback Statute
In addition, Ross is an expert witness at the request of Relator’s attorneys, the Greene Law Firm, in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen Inc.
Jan 1, 2022 | healthaffairs.orgBiogen, Inc. partnered with MedRhythms, Inc. on May 6th 22'.
Biogen is bolstering its multiple sclerosis (MS) pipeline through a licensing agreement with Maine-based MedRhythms for its investigational digital therapeutic MR-004, which is being assessed for the potential treatment of gait deficits in MS. This morning, Biogen said the partnership combines its leadership and global footprint in MS with MedRhythms’ digital expertise.
Jan 1, 2022 | biospace.comMichel Vounatsos left Biogen, Inc. as CEO on May 10th 22'.
Massachusetts : Biogen on Tuesday announced that CEO Michel Vounatsos, who has led the company since 2016, is stepping down.
Jan 1, 2022 | advisory.comLifshitz & Miller files suit against Biogen, Inc.
Lifshitz Law PLLC announces that a class action complaint has been filed against Biogen alleging that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Biogen's business, operations, and prospects.
Jan 1, 2022 | benzinga.comBiogen, Inc. is developing investigational digital therapy to help multiple sclerosis patients improve gait using music
Biogen and MedRhythms will develop an investigational digital therapy to help multiple sclerosis patients improve their gait using music, software, and sensors.
Jan 1, 2022 | medpagetoday.comBiogen, Inc. is developing treatments for Alzheimer’s disease on Mar 20th 22'.
(https://bit.ly/3g3MlFm) March, 2014: Eisai Co Ltd agrees to collaborate with Biogen to develop treatments for Alzheimer’s disease, including an option for the Tokyo-based company to jointly develop and commercialize aducanumab.
Jan 1, 2022 | kelo.comBiogen, Inc. has issues with potential breaches of fiduciary duties
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Biogen Inc.
Jan 1, 2022 | openpr.comBiogen, Inc. is developing zuranolone for major depressive disorder on Jun 1st 21'.
Sage and Biogen, both based in Cambridge, Mass., late last year signed a global collaboration and license agreement to jointly develop and commercialize zuranolone for major depressive disorder, postpartum depression and other psychiatric disorders.
Jan 1, 2022 | marketwatch.comAaron Deykin leaves Biogen, Inc. as SVP head of clinical sciences
Aaron Deykin joined Upstream Bio as chief medical officer and head of research and development from Biogen, where he was SVP head of clinical sciences.
Jan 1, 2022 | labiotech.euBiogen, Inc. launches Byooviz as the first biosimilar product to Lucentis for the treatment of neovascular
Biogen and Samsung Bioepis have announced the US launch of Byooviz™ (ranibizumab-nuna) as the first biosimilar product to Lucentis (ranibizumab) for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization.
Jan 1, 2022 | empr.comBiogen, Inc. partnered with Alectos Therapeutics Inc. on May 30th 22'.
Biogen announced a deal with Canadian biotech Alectos Therapeutics on Monday to develop a drug aimed at restoring lysosome function, adding another candidate to the pharma’s Parkinson’s pipeline.
Jan 1, 2022 | endpts.comBiogen, Inc. launches Byooviz in the US
Biogen and Samsung Bioepis announced the launch of Byooviz™ (biosimilar ranibizumab ) in the US.
Jan 1, 2022 | lexology.comBiogen, Inc. is developing AL01811
Biogen and Alectos Therapeutics have entered into a license and collaboration agreement to develop and commercialize a novel preclinical selective GBA2 inhibitor, AL01811, which has first-in-class potential as an oral disease modifying treatment for patients with Parkinson’s disease (PD).
Jan 1, 2022 | pharmafocusasia.comBiogen, Inc. launched När Livet Vänder on May 30th 22'.
On World MS Day, May 30 th, N365 and the pharmaceutical company Biogen launched “När Livet Vänder.”
Jan 1, 2022 | n365group.comMedical Buyer partners with Biogen, Inc.
Medical Buyer is very excited to partner with Biogen on this opportunity given their leadership in the MS space.”
Jan 1, 2022 | medicalbuyer.co.inBiogen, Inc. partners with Zuellig Pharma Pte. Ltd.
Along with Almirall and Biogen, the company has also teamed up with Zuellig Pharma on prescription digital therapeutics in Asia and with health insurance company Anthem (shortly to be known as Elevance) on a digital support tool focused on women’s health, including pregnancy and menopause.
Jan 1, 2022 | pharmaphorum.comDtxalliance partners with Biogen, Inc.
Dtxalliance is very excited to partner with Biogen on this opportunity given their leadership in the MS space.”
Jan 1, 2022 | happifyhealth.comHappify, Inc. partners with Biogen, Inc.
Digital therapeutic maker Happify Health is partnering with neuroscience-focused pharma company Biogen on a digital engagement and education platform for multiple sclerosis.
Jan 1, 2022 | guidedsolutions.co.ukDigital Health Global partners with Biogen, Inc.
Digital Health Global is very excited to partner with Biogen on this opportunity given their leadership in the MS space.”
Jan 1, 2022 | digitalhealthglobal.comMobihealthnews partners with Biogen, Inc.
Mobihealthnews is very excited to partner with Biogen on this opportunity given their leadership in the MS space."
Jan 1, 2022 | mobihealthnews.comPharmafocusasia partners with Biogen, Inc.
Pharmafocusasia is very excited to partner with Biogen on this opportunity given their leadership in the MS space.”
Jan 1, 2022 | pharmafocusasia.comBiogen, Inc. is developing BIIB059
Apart from this, Biogen is developing, BIIB059, is an investigational humanized monoclonal antibody that specifically recognizes and binds to blood DC antigen 2 (BDCA2), a pDC-specific receptor that inhibits the production of IFN-I and other inflammatory mediators when ligated.
Jan 1, 2022 | prnewswire.comUnilabs Group signs new client Biogen, Inc.
Unilabs has been selected by Biogen Idec to provide a companion diagnostic anti-JCV antibody assay test, called STRATIFY-JCV.
Jan 1, 2022 | yorkbio.comLivin Well Life partners with Biogen, Inc.
Livin Well Life is very excited to partner with Biogen on this opportunity given their leadership in the MS space.”
Jan 1, 2022 | livinwellife.comBiogen, Inc. launches aducanumab as Aduhelm
In this case, the FDA ruled that Biogen could release aducanumab as Aduhelm as long as it continued to collect clinical data.
Jan 1, 2022 | maryebblaw.comBiogen, Inc. launches advertisement to raise awareness of SMA in Spain
With the expansion of newborn screening tests for diagnosing Spinal Muscular Atrophy(SMA) in Europe, Biogen has created an advertisement to raise awareness of SMA in Spain.
Jan 1, 2022 | 3billion.ioBio-Thera partnered with Biogen, Inc. on Apr 1st 21'.
“This agreement allows Bio-Thera Solutions and Biogen to bring a potentially new biosimilar option to patients.”
Apr 8, 2021 | globenewswire.comAtalantatx partners with Biogen, Inc.
Additionally, Atalanta announced strategic collaborations with Biogen (Nasdaq: BIIB) and Genentech, a member of the Roche Group.
Jan 1, 2021 | atalantatx.comAPRINOIA Therapeutics partners with Biogen, Inc.
“APRINOIA Therapeutics is excited to announce its collaboration with Biogen.
Jan 1, 2020 | aprinoia.comNorthern Trust Company invests into Biogen, Inc.
Northern Trust Corporation has invested 0.25% in Biogen Inc. (NASDAQ:BIIB).
Jan 1, 2019 | cryptocoinstribune.comMorgan Stanley invests into Biogen, Inc.
The New York-based Morgan Stanley has invested 0.06% in Biogen Inc. (NASDAQ:BIIB).
Jan 1, 2019 | makdaily.comThe Burney Company invests into Biogen, Inc.
Burney Co has invested 0.87% of its capital in Biogen Inc. (NASDAQ:BIIB).
Jan 1, 2019 | kreviewer.comTerrilco invests into Biogen, Inc.
Terril Brothers invested 3.9% in Biogen Inc. (NASDAQ:BIIB).
Jan 1, 2019 | altcoinmercury.comBiogen, Inc. acquired Neurocrine Biosciences, Inc. on Jan 1st 19'.
In addition, STAT reveals that Biogen had a plan to acquire Neurocrine Biosciences (NBIX) in 2019 that did not come to fruition.
Jan 1, 2019 | xyftthefly.comBiogen, Inc. launched three-year data cut showing on Jul 1st 19'.
At the European Academy of Neurology (EAN) meeting in Oslo today Biogen unveiled a three-year data cut showing that after treatment 88% of patients can walk independently, and 92% with some assistance; all are alive and none require permanent ventilation.
Jan 1, 2019 | evaluate.comSamsung Electronics Co. partners with Biogen, Inc.
The Samsung group has collaborated with Biogen in developing its contract drugmaking business.
Jan 1, 2018 | nikkei.comSamsung Electronics Co. partners with Biogen, Inc.
The Samsung group has collaborated with Biogen in developing its contract drugmaking business.
Jan 1, 2018 | nikkei.comTrillium invests into Biogen, Inc.
Trillium Asset Management Ltd has invested 0.54% in Biogen Inc. (NASDAQ:BIIB).
Jan 1, 2018 | cardinalweekly.comBiogen, Inc. acquired Samsung Bioepis Co., Ltd. on Jun 1st 18'.
Cambridge, Mass.-based Biogen exercised its option to acquire additional shares of South Korea’s Samsung Bioepis.
Jan 1, 2018 | biospace.comAmica Mutual Com invests into Biogen, Inc.
Amica Mutual Ins has invested 0.26% in Biogen Inc. (NASDAQ:BIIB).
Jan 1, 2018 | enbulletin.com